Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lu-177 PSMA-617
DRUG
2 trials
Sponsors
Radboud University Medical Center
, Ankara University
Conditions
Metastatic Renal Cancer
Prostate Neoplasm
Phase 1
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Completed
NCT03828838
Radboud University Medical Center
Prostate Neoplasm
Start: 2018-07-01
End: 2019-11-01
Updated: 2019-11-14
Phase 3
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Not yet recruiting
NCT06959433
Ankara University
Metastatic Renal Cancer
Start: 2026-05-01
End: 2028-08-01
Target: 20
Updated: 2026-02-27
Related Papers
The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
2023-04-20
7 citations
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
EJNMMI Research
2023-01-24
36 citations
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study
Clinical Cancer Research
2021-04-21
89 citations
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
2020-09-14
32 citations
Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging
2019-12-26
56 citations